Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015
December 11, 2018
Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting
Download PDF format download (opens in new window)
December 05, 2018
Aptinyx to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
Download PDF format download (opens in new window)
December 03, 2018
Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia
Download PDF format download (opens in new window)
November 13, 2018
Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights
Download PDF format download (opens in new window)
November 12, 2018
Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans
Download PDF format download (opens in new window)
November 01, 2018
Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy
Download PDF format download (opens in new window)
October 29, 2018
Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the Society for Neuroscience
Download PDF format download (opens in new window)
September 25, 2018
Aptinyx to Present at Cantor Fitzgerald Global Healthcare Conference
Download PDF format download (opens in new window)
September 14, 2018
Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pain’s 17th World Congress on Pain
Download PDF format download (opens in new window)
August 21, 2018
Aptinyx Presents Preclinical Data from Fast-Track Designated PTSD Program at Military Health System Research Symposium
Download PDF format download (opens in new window)
August 14, 2018
Aptinyx Reports Second Quarter 2018 Financial and Business Results
Download PDF format download (opens in new window)
August 02, 2018
Aptinyx Initiates Phase 1 Study of NYX-458
Download PDF format download (opens in new window)
June 25, 2018
Aptinyx Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Download PDF format download (opens in new window)
June 20, 2018
Aptinyx Announces Pricing of Initial Public Offering
Download PDF format download (opens in new window)
May 22, 2018
Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration
Download PDF format download (opens in new window)
May 17, 2018
Aptinyx Appoints Robert Hombach to Board of Directors
Download PDF format download (opens in new window)
May 03, 2018
Aptinyx Promotes David Houck to Chief Development Officer
Download PDF format download (opens in new window)
March 21, 2018
Aptinyx to Present at Needham & Company’s 17th Annual Healthcare Conference
Download PDF format download (opens in new window)
March 15, 2018
Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson’s Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018
Download PDF format download (opens in new window)
March 12, 2018
Aptinyx to Present at 38th Annual Cowen Health Care Conference
Download PDF format download (opens in new window)
March 08, 2018
Aptinyx Presents Preclinical and Phase 1 Clinical Data on NYX-2925 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
Download PDF format download (opens in new window)
March 06, 2018
Aptinyx Presents NYX-2925 Preclinical Data in Chemotherapy-induced Neuropathic Pain at the American Pain Society Annual Scientific Meeting
Download PDF format download (opens in new window)
February 13, 2018
Aptinyx Appoints Ashish Khanna Chief Financial Officer and Chief Business Officer
Download PDF format download (opens in new window)